Cargando…

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy

SIMPLE SUMMARY: Regorafenib and TAS-102 showed a survival benefit against placebo, and both drugs are approved for the treatment of metastatic colorectal cancer (mCRC) beyond second-line. The highly differential toxicity profile of both substances has led to a potentially biased perception of drug t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huemer, Florian, Piringer, Gudrun, Schlintl, Verena, Hackl, Hubert, Rinnerthaler, Gabriel, Thaler, Josef, Greil, Richard, Weiss, Lukas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599669/ https://www.ncbi.nlm.nih.gov/pubmed/33007814 http://dx.doi.org/10.3390/cancers12102812

Ejemplares similares

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
por: Huemer, Florian, et al.
Publicado: (2018)

A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
por: Su, Guan-Li, et al.
Publicado: (2020)

Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort
por: Schlintl, Verena, et al.
Publicado: (2022)

Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
por: Sugiura, Kiyoaki, et al.
Publicado: (2021)

A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiaochen, et al.
Publicado: (2021)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer
por: Huemer, Florian, et al.
Publicado: (2018)

Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials
por: Chen, Jianxin, et al.
Publicado: (2019)

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
por: Chen, Duke, et al.
Publicado: (2018)

Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
por: Conti, Matteo, et al.
Publicado: (2023)

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
por: Huemer, Florian, et al.
Publicado: (2019)

Management of metastatic colorectal cancer in patients ≥70 years - a single center experience
por: Huemer, Florian, et al.
Publicado: (2023)

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

TAS-102 and the quest for predictive biomarkers
por: van der Velden, Daphne L, et al.
Publicado: (2017)

Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report
por: Kamei, Hideki, et al.
Publicado: (2016)

TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
por: Petrelli, Fausto, et al.
Publicado: (2016)

A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
por: Unseld, Matthias, et al.
Publicado: (2020)

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
por: Van Cutsem, Eric, et al.
Publicado: (2017)

Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
por: Huemer, Florian, et al.
Publicado: (2020)

Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
por: Fujii, Hironori, et al.
Publicado: (2019)

Drug-induced Pneumonitis Following the Administration of TAS-102
por: Hasegawa, Yoshikazu, et al.
Publicado: (2016)

Difference in Neutropenia due to Administration Schedule of TAS-102
por: Yoshida, Yoichiro, et al.
Publicado: (2017)

Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and Age
por: Niedersüß-Beke, Dora, et al.
Publicado: (2021)

Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol
por: Huemer, Florian, et al.
Publicado: (2022)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer—Results from the AGMT GASTRIC-5 Registry
por: Huemer, Florian, et al.
Publicado: (2020)

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial
por: Rinnerthaler, Gabriel, et al.
Publicado: (2020)

Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis
por: Rumpold, Holger, et al.
Publicado: (2020)

Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics
por: Huemer, F, et al.
Publicado: (2019)

Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2015)

Feasibility of 7-T fluorine magnetic resonance spectroscopic imaging ((19)F MRSI) for TAS-102 metabolite detection in the liver of patients with metastatic colorectal cancer
por: Kurk, Sophie A., et al.
Publicado: (2018)

Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme
por: Sforza, Vincenzo, et al.
Publicado: (2017)

TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study
por: Cicero, Giuseppe, et al.
Publicado: (2020)

Prophylactic use of pegfilgrastim enables the management of severe neutropenia without dose delays in patients with metastatic colorectal cancer treated with TAS-102 plus bevacizumab
por: Tamaki, Sawako, et al.
Publicado: (2022)

Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
por: Satake, Hironaga, et al.
Publicado: (2020)

Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
por: Li, Qizheng, et al.
Publicado: (2022)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q7c544p9q8isfq952l8eancgc7